OSE’s R&D team and its academic partners have characterized the myeloid checkpoint CLEC-1 (a C-type lectin receptor) as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel “Don’t Eat Me” signal.


CLEC-1 antagonist monoclonal antibodies have been identified as an innovative cancer immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells’ antigen presentation and demonstrates synergistic anti-cancer effects, in particular when paired with chemotherapy.

The identification of CLEC-1 and its antagonists constitute an exciting innovative step in cancer immunotherapy.

This research program is being conducted in collaboration with Dr. Elise Chiffoleau (Center for Research in Transplantation and Immunology, UMR – INSERM 1064, Nantes University Hospital)

To receive OSE Immunotherapeutics’ latest news